Drug
Tissue Plasminogen Activator clinical trials
Also written Alteplase, Activase, Actilyse and rt-PA.
- studies test it
- 119
- open now
- 10
- in phase 3
- 42
- first study started
- 1993
Keep track of what changes. Save the Tissue Plasminogen Activator studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
- tPA
- 16
Combined with it in one product
Studies by the year they started
117 studies that test it; most in 2019 (9)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1998 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 6 |
| 2005 | 4 |
| 2006 | 2 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 9 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 14
- Phase 2
- 30
- Phase 3
- 42
- Phase 4
- 22
- No phase
- 16
What it is tested for
Each study’s main condition, where its own words name it.
- Stroke
- 10
Who runs them
Industry 16 · Other 103
Johns Hopkins University (5) · Kafrelsheikh University (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Boehringer Ingelheim (3) · Thrombolex, Inc. (3) · Boston Scientific Corporation (3) · Tanabe Pharma Corporation (2) · University of Calgary (2)
Often tested with
Tested in the same studies.
Tenecteplase (7) · Streptokinase (2) · Heparin (2) · auR protein, Staphylococcus aureus (1) · Deoxyribonucleases (1) · Deoxyribonuclease I (1) · Perflutren (1) · Warfarin (1)
Studies
Open first, then newest update. How each study uses Tissue Plasminogen Activator is read from its arms, and is right about nine times in ten.
Testing it · 119
- INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical ThrombectomyRecruitingPhase 3115 People's HospitalNCT07727395Written as Alteplase
- Thrombolysis in Factor Xa-inhibitors TrialRecruitingPhase 3Guri HagbergNCT06878066Written as thrombolysis therapy
- Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel OcclusionRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT07668323Written as Recombinant Tissue Plasminogen Activator (rt-PA)
- Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).RecruitingPhase 3King's College Hospital NHS TrustNCT04663750Written as subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural EffusionRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT06184321Written as Alteplase
- CleaRRAflow: Isotonic Solution vs. TPA for IVH ClearanceEnrolling by invitationPhase 4David DornbosNCT07643493Written as Tissue Plasminogen Activator (tPA)
- The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary EmbolismRecruitingNot applicableThrombolex, Inc.NCT06433011Written as r-tPA
- the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke PatientsRecruitingPhase 4Kafrelsheikh UniversityNCT06653946Written as Alteplase
- Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory FailureRecruitingPhase 2South West Sydney Local Health DistrictNCT05540834Written as Alteplase
- Application of tPA in Suprachoroidal and Subretinal HemorrhageRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05736757Written as Tissue Plasminogen Activator
- Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)CompletedPhase 2/3Chinese University of Hong KongNCT05766124Written as Tissue Plasminogen Activator
- Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical ThrombectomyCompletedPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05856851Written as Alteplase
- Pulmonary Embolism International THrOmbolysis Study-3Active, not recruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT04430569Written as Alteplase
- Adjunctive, Low-dose tPA in Primary PCI for STEMICompletedPhase 3Population Health Research InstituteNCT03335839Written as tissue plasminogen activator
- Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural HematomasCompletedPhase 4Hamilton Health Sciences CorporationNCT05491356Written as Tissue Plasminogen Activator
- To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve ThrombosisCompletedNot applicableU. N. Mehta Institute of Cardiology and Research CenterNCT07360717Written as Alteplase
- Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）CompletedPhase 4Tanabe Pharma CorporationNCT00412867Written as Alteplase
- Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic StrokeCompletedPhase 3Tanabe Pharma CorporationNCT00147316Written as Alteplase
- Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive StrokeCompletedNot applicableSichuan Academy of Medical SciencesNCT05631847Written as Intravenous thrombolysis (Alteplase)
- Predictors of Post-alteplase Hemorrhagic Transformation of Brain InfarctionCompletedPhase 4Kafrelsheikh UniversityNCT06337175Written as Alteplase
See all 119 studies that test Tissue Plasminogen Activator →
Given in every arm · 15 — Tissue Plasminogen Activator is usual care beside what is tested
- Study on Hibernation-like Therapy Based on Mechanical ThrombectomyRecruitingPhase 1Capital Medical UniversityNCT06663631Written as rt-PA
- Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke：Longterm Outcome (OPENS-3L)RecruitingPhase 3Ji Xunming,MD,PhDNCT05965193Written as Intravenous thrombolysis(rt-PA)
- Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)CompletedPhase 3Ji Xunming,MD,PhDNCT05965687Written as Intravenous thrombolysis(rt-PA)
- Argatroban Plus R-tPA for Acute Ischemic StrokeCompletedPhase 4General Hospital of Shenyang Military RegionNCT03740958Written as rt-PA
- Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary EmbolismTerminatedPhase 4Victor Tapson, MDNCT03988842Written as Alteplase
- Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)CompletedPhase 3The Hospital for Sick ChildrenNCT01717742Written as TPA (Tissue Plasminogen Activator)
- Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery OcclusionWithdrawnPhase 2University Hospital Center of MartiniqueNCT02338466Written as rt-PA
- SITS (Safe Implementation of Treatments in Stroke) Open Artery by Thrombectomy in Acute Occlusive Stroke StudyCompletedNot applicableKarolinska InstitutetNCT02326428Written as Intravenous thrombolysis by alteplase (Actilyse) (optional)
- Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic StrokeTerminatedNot applicableCentral Hospital, Nancy, FranceNCT01062698Written as Alteplase (rt-PA)/Actilyse
- Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute StrokeTerminatedPhase 2Andrew D. Barreto, MDNCT01464788Written as rt-PA (alteplase)
- A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPAStatus unknownPhase 2D-Pharm Ltd.NCT02572336Written as Tissue Plasminogen Activator (tPA)
- Pragmatic Ischaemic Stroke Thrombectomy EvaluationTerminatedNot applicableNHS Greater Glasgow and ClydeNCT01745692Written as Intravenous rtPA
- Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic StrokeCompletedPhase 2Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNCT01678495Written as Recombinant tissue plasminogen activator
- Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device OcclusionCompletedPhase 3Boehringer IngelheimNCT01958164Written as Actilyse
- Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic StrokeCompletedPhase 2University of CincinnatiNCT00894803Written as rt-PA
As the comparator · 31 — what is tested is compared with Tissue Plasminogen Activator
- Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical TrialRecruitingPhase 4Nippon Medical SchoolNCT07111559Written as rt-PA
- Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion StrokeRecruitingPhase 3Xuanwu Hospital, BeijingNCT06658197Written as Alteplase
- Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor StrokeNot yet recruitingPhase 4Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05910125Written as Alteplase
- Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5CompletedPhase 3Beijing Tiantan HospitalNCT06196320Written as Best Practice (which may include intravenous Alteplase)
- Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial InfarctionCompletedPhase 3AO GENERIUMNCT07146360Written as Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AISCompletedPhase 3Supergene, LLCNCT03151993Written as Alteplase
- A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical ActivityCompletedPhase 3Boehringer IngelheimNCT04915729Written as alteplase
- Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) FunctionalityTerminatedPhase 3Chiesi Farmaceutici S.p.A.NCT03594175Written as Alteplase
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)CompletedPhase 3Tasly Biopharmaceuticals Co., Ltd.NCT05700591Written as rt-PA
- Alteplase-Tenecteplase Trial Evaluation for Stroke ThrombolysisCompletedPhase 3NHS Greater Glasgow and ClydeNCT02814409Written as Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
- A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）CompletedPhase 3Angde Biotech Pharmaceutical Co., Ltd.NCT05295173Written as Recombinant human tissue plasminogen activator
- Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic StrokeCompletedPhase 2Erasmus Medical CenterNCT04256473Written as Alteplase
- Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ）Status unknownPhase 3Beijing Tiantan HospitalNCT05745259Written as Alteplase
- Antiplatelet vs R-tPA for Acute Mild Ischemic StrokeCompletedPhase 4General Hospital of Shenyang Military RegionNCT03661411Written as Alteplase
- The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMICompletedPhase 4Guangzhou Recomgen Biotech Co., Ltd.NCT02835534Written as alteplase
- Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）Status unknownPhase 2Beijing Tiantan HospitalNCT05281549Written as Alteplase
- Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic StrokeCompletedPhase 4Hui-Sheng ChenNCT03394950Written as rtPA
- A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary EmbolismCompletedPhase 2Tasly Biopharmaceuticals Co., Ltd.NCT03108833Written as Alteplase
- Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)CompletedPhase 3Tasly Biopharmaceuticals Co., Ltd.NCT03541668Written as Alteplase
- Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)Status unknownPhase 2Angde Biotech Pharmaceutical Co., Ltd.NCT04110275Written as Recombinant human tissue-type plasminogen activator
Showing 20 of 31.
Codes
What other systems call Tissue Plasminogen Activator · ClinicalTrials.gg INT008043
- MeSH (NLM) D010959Tissue Plasminogen ActivatorOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D010959 | Tissue Plasminogen Activator | One source ClinicalTrials.gov |
Also registered as alteplase (UNII 1RXS4UE564 · RxNorm 8410) and tissue-type plasminogen activator (UNII 1SBRUI0C8R).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.